SynCore Biotechnology Co (ROCO:4192) Valuation Rank

View and export this data going back to 2014. Start your Free Trial

What is SynCore Biotechnology Co Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

Three factors:
- Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
- Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
- Industry relative valuation
Companies without enough data is not ranked
Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

SynCore Biotechnology Co Valuation Rank Related Terms

Thank you for viewing the detailed overview of SynCore Biotechnology Co's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

SynCore Biotechnology Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SynCore Biotechnology Co Ltd (ROCO:4192) » Definitions » Valuation Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.84 Zhongshan Road, Zhongshan Village, Dongshan Township, Yilan, TWN, 269

Website

https://www.syncorebio.com

SynCore Biotechnology Co Ltd is a biopharmaceutical company. Its pipeline products concentrate on the ophthalmology, oncology, and dermatology fields. The pipeline products of the company include SB01 and 02, SB03, SB04, and SB05. It is engaged in drug development and sale, food advisory, medicine inspection, biotechnology service and intellectual property. It operates in a single industry, the new drug development.